CM
KYNB

Castleark Management’s Kyntra Bio KYNB Stock Holding History

Castleark Management’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-3,007
Closed -$4.57M – 382
2018
Q3 		$4.57M Buy
+3,007
New +$4.63M 0.13% 201
2018
Q1 		– Sell
-4,361
Closed -$5.17M – 416
2017
Q4 		$5.17M Sell
4,361
-3,891
-47% -$4.88M 0.16% 186
2017
Q3 		$11.1M Buy
8,252
+3,622
+78% +$3.82M 0.35% 97
2017
Q2 		$3.74M Sell
4,630
-1,094
-19% -$762K 0.12% 207
2017
Q1 		$3.53M Buy
+5,724
New +$3.49M 0.11% 223

Other funds holding KYNB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Castleark Management's KYNB Position: Q4 2018 in Review

Castleark Management sold out of Kyntra Bio (KYNB) in Q4 2018, closing a stake of 3,007 shares — an estimated $4.57M sold.

Castleark Management first reported a position in KYNB in Q1 2017 and held it in 5 quarters. The position peaked at $11.1M in Q3 2017. 201 funds tracked by Wall St. Rank hold KYNB as of Q4 2018.

  • Castleark Management reported no remaining Kyntra Bio position as of Q4 2018 after selling out during the quarter.
  • Castleark Management sold 3,007 Kyntra Bio shares in Q4 2018, an estimated $4.57M.
  • Castleark Management first reported a position in Kyntra Bio in Q1 2017 and held it in 5 quarters.
  • Castleark Management's Kyntra Bio position peaked at $11.1M in Q3 2017.
  • 201 funds tracked by Wall St. Rank held Kyntra Bio as of Q4 2018.

Based on Castleark Management's 13F filing for Q4 2018, filed 12 Feb 2019.